{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-199416","form_type":"8-K","ticker":"XOMA","cik":"0000791908","company_name":"XOMA Royalty Corp","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.891768+00:00","generated_at":"2026-05-31T09:54:55.849818+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"XOMA Royalty Q2 net income $16.0M; receives $22.6M cash; acquires Kinnate and Daré rights; posts $9.0M impairment","bullets":["Net income $16.0M vs net loss $5.4M in Q2 2023; total income/revenue $11.1M; cash receipts $22.6M.","Completed acquisition of Kinnate Pharmaceuticals, adding >$9.5M cash and potential royalty streams; acquired Daré's XACIATO, Ovaprene, Sildenafil Cream rights.","Recorded $9.0M non-cash impairment on Aronora programs; $19.3M gain on Kinnate acquisition, partially offset by $8.1M derivative charge.","Zevra's arimoclomol received favorable advisory committee vote; FDA PDUFA date Sept 21, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-199416","json":"https://secwatch.observer/filing/0001193125-24-199416.json","markdown":"https://secwatch.observer/filing/0001193125-24-199416.md","text":"https://secwatch.observer/filing/0001193125-24-199416.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/791908/000119312524199416/0001193125-24-199416-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/791908/000119312524199416/d829744d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:54:55.849818+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}